The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Latest on Epigenetics in Immune-Mediated Disease

The Latest on Epigenetics in Immune-Mediated Disease

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

From Bench to Bedside

The session concluded with presentations on two abstracts from the conference. Chris M. Dunn, a master’s student at the University of Oklahoma Health Sciences Center, Oklahoma City, presented his research, titled, “Epigenetic Editing of FOXP3 in Human T Cells Is Sufficient to Induce Overexpression and Create a Regulatory T Cell Phenotype in Vitro.”

You Might Also Like
  • Did Shiitake Mushrooms Induce Immune-Mediated Necrotizing Myopathy?
  • The Latest on Vaccinations, Leprosy & Lyme Disease
  • Rheuminations: Epigenetics May Help to Explain Why Some Get Rheumatic Disease
Explore This Issue
March 2019
Also By This Author
  • Early Onset of Primary Sjögren’s Syndrome May Carry a Worse Prognosis

Mr. Dunn described the epigenetic editing of the transcription factor FOXP3 using a dCas9-TET1 construct. He acknowledged, “There is a hot debate on whether FOXP3 expression and CTLA4 expression are related in any way.” Nevertheless, his team was able to induce DNA demethylation, overexpression and a regulatory T cell phenotype.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Our data are intriguing but need confirmation, particularly to clarify the persistence of induced DNA methylation changes and resistance to phenotype switching. If confirmed, this approach has the potential to significantly improve upon current methods of Treg [regulatory T cell] generation,” he explained.

Jieun Shin, PhD, with the Research Institute of Chong Kun Dang Pharma­ceutical Corp., Yongin, Korea, presented her group’s research on CKD-506, a first-in-class selective and potent histone deacetylase (HDAC) 6 inhibitor. Dr. Shin reported data from ex vivo studies of RA patient samples, as well as data from the rat adjuvant-induced arthritis (AIA) model. She began her presentation by describing a macrophage cell line that overexpressed HDAC6 and had increased production of inflammatory cytokines. When she and her colleagues treated these cells with CKD-506, they were able to inhibit the inflammatory mediators and inhibit NF-kB and AP-1 signaling in the cells.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When the investigators treated RA patient samples with CKD-506, they were also able to inhibit inflammatory mediators, specifically TNF-α. In addition, CKD-506 induced IL-10 production when RA patient peripheral blood mononuclear cells were stimulated with lipopolysaccharide. When they looked at cellular function, they found CKD-506 induced CTLA4 and enhanced Treg activity in PBMCs from patients with RA. Specifically, CD4+CD25– cells differentiated into Treg cells in the presence of CKD-506. Dr. Shin and her colleagues then orally administered CKD-506 to AIA rats and found it not only repressed arthritis in the rats, but it also acted synergistically with methotrexate.

CKD-506 improved symptoms of RA via regulation of inflammation and T cell function, according to Dr. Shin. CKD-506 is currently in preparation for a phase 2a clinical trial in the European Union for the treatment of patients with moderate to severe RA. The team is also exploring the possibility CKD-506 will be effective in the treatment of inflammatory bowel disease.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, epigenetics, epigenomeIssue: March 2019

You Might Also Like:
  • Did Shiitake Mushrooms Induce Immune-Mediated Necrotizing Myopathy?
  • The Latest on Vaccinations, Leprosy & Lyme Disease
  • Rheuminations: Epigenetics May Help to Explain Why Some Get Rheumatic Disease
  • FOCIS 2015: Metabolism May Affect Immune System’s Reaction to Disease

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)